2017年 3月 3日
EMERGO SUMMARY OF KEY POINTS:
The South Korean Ministry of Food and Drug Safety (MFDS) has issued clarifications on medical device registration and quality system requirements whose enforcement dates are imminent.
Emergo consultants in Seoul report that South Korean regulators have updated the Medical Device Act No. 14330 as well as the Regulation on KGMP No. 2016-156 (links in Korean) to more fully explain rules for unique device identification (UDI), expenditure reports and Korea Good Manufacturing Practice (KGMP) quality system audit procedures.
First, the MFDS has clarified plans to phase in UDI requirements for all classes of medical devices over the next several years, and further explained associated compliance obligations for registration holders.
“The current law for medical devices provides little basis for understanding a device’s status from its production or importation stage to its distribution stage,” says In-Wha Kim, Regulatory Affairs Specialist at Emergo’s South Korea office.
Therefore, according to Kim, MFDS will be introducing a UDI system, requiring manufacturers, importer and distributors to report supply histories, and establish a Medical Device Information Center according to a seminar the ministry held in January 2017.
UDI enforcement would come into effect in 2019 for Class IV and high-risk devices; 2020 for Class III devices; 2021 for Class II devices; and 2022 for low-risk Class I devices.
MFDS added the following specific clarifications to its UDI regulation:
Second, South Korean regulators have simplified audit procedures and documentation requirements for KGMP quality management system compliance. These changes took effect March 1, 2017.
KGMP audit changes include:
Finally, MFDS has explained how frequently South Korean market registrants must provide expenditure reports on how their devices provide economic benefits to healthcare providers and institutions.
Registrants must generate expenditure reports annually, within three months of their fiscal year ends. They must also retain these reports along with relevant supporting data for five years; South Korean regulators may request these reports at any time.
“It is not easy to distinguish or detect whether the provision of some economic benefit to a healthcare provider is related to promoting the sale of a device,” explains Kim. “As a countermeasure to this, medical device companies are obliged to prepare expenditure reports on providing economic benefits, which is intended to strengthen registrants’ own self-reporting and monitoring capabilities, and ensure more transparency in the market.”
According to MFDS, expenditure reporting requirements take effect on June 3, 2017.
For more information on South Korea’s medical device market, read our MFDS registration whitepaper, watch our video overview and download our regulatory process chart.